MeCP2 facilitated breast cancer cell proliferation and inhibited cell apoptosis through suppressing RPL11 and RPL5 expression by binding to their promoter regions, thereby promoting ubiquitination-mediated P53 degradation. Here, RPL11 is linked to breast carcinoma.